Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PhaseBio Pharmaceuticals, Inc. - Common Stock (NQ:PHAS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Nov 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PhaseBio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Trevi Therapeutics (NASDAQ:TRVI) stock rose 45.8% to $2.77 during Thursday's regular session. Trevi Therapeutics's stock is trading at a volume of 15.2... 
Via Benzinga
News headline image
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
During Monday's session, 291 companies made new 52-week lows. Also check out this: Insiders Buying These 4 Penny Stocks Noteable 52-Week Lows And Highs: SAP (... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Yumanity Therapeutics (NASDAQ:YMTX) shares rose 13.3% to $1.7 during Friday's pre-market session. The market value of their outstanding shares is at $18.4... 
Via Benzinga
News headline image
53 Biggest Movers From Yesterday ↗
Gainers IGM Biosciences, Inc. (NASDAQ: IGMS) shares gained 96.7% to settle at $29.49 on Tuesday. Sanofi SA (NASDAQ: SNY) and IGM Biosciences signed an exclusive worldwide... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers IGM Biosciences (NASDAQ:IGMS) shares rose 114.8% to $32.2 during Tuesday's regular session. IGM Biosciences's stock is trading at a volume of 31.6 million... 
Via Benzinga
News headline image
Looking Into PhaseBio Pharmaceuticals's Return On Capital Employed ↗
Benzinga Pro data, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported Q4 sales of $158.00 thousand. Earnings fell to a loss of $43.11 million, resulting in a 35.04% decrease from... 
Via Benzinga
News headline image
63 Biggest Movers From Yesterday ↗
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... 
Via Benzinga
News headline image
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Allego N.V. (NYSE: ALLG) shares surged 114.1% to close at $17.73 on Wednesday after the company announced the completion of its merger agreement with Spartan Acquisition... 
Via Benzinga
News headline image
PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The largest company by market cap to set a new 52-... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week... 
Via Benzinga
News headline image
52 Weeks High And Low Article ↗
On Friday, 106 companies reached new 52-week lows. Things to Consider About Today's 52-Week Lows: Air Products & Chemicals (NYSE:APD) is the largest company... 
Via Benzinga
News headline image
PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
PhaseBio Pulls Plug On Mid-Stage Hypertension Asset ↗
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The... 
Via Benzinga
News headline image
PhaseBio Provides Pemziviptadil (PB1046) Program Update
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
Tuesday's session saw 109 companies set new 52-week lows. Interesting Points From Today's 52-Week Highs And Lows: The largest company in terms of market cap... 
Via Benzinga
News headline image
PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Cumberland (NASDAQ:CPIX) share... 
Via Benzinga
News headline image
PhaseBio Names Jonathan Birchall as Chief Commercial Officer
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Rani Therapeutics Hldgs (NASDAQ:RA... 
Via Benzinga
News headline image
70 Biggest Movers From Yesterday ↗
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
News headline image
PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect ↗
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of... 
Via Benzinga
News headline image
PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
News headline image
PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
News headline image
PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study ↗
PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The... 
Via Benzinga
News headline image
PhaseBio Announces Topline Results From Phase 2b Trial for Bentracimab
From PhaseBio Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.